Article Contents ::
- 1 The Brand Name CELLMUNE Has Generic Salt :: Mycophenolate
- 2 CELLMUNE Is From Company Cipla Priced :: Rs. 880
- 3 CELLMUNE have Mycophenolate is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CELLMUNE Has Generic Salt :: Mycophenolate
CELLMUNE Is From Company Cipla Priced :: Rs. 880
CELLMUNE have Mycophenolate is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Mycophenolate | TAB | Rs. 880 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| CELLMUNE | Cipla | 500MG | 10 | Rs. 880 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Cipla :: CELLMUNE | Mycophenolate | #N/A | #N/A |
Indications for Drugs ::
Prophylaxis of acute renal graft rejection
Drug Dose ::
Adult: PO Prophylaxis of acute renal graft rejection As mycophenolate mofetil (MMF): 1 g twice daily starting w/in 72 hr of transplantation. Max: 2 g/day. As mycophenolic acid: 720 mg twice daily. Prophylaxis of cardiac graft rejection As MMF: 1.5 g twice daily starting w/in 5 days after transplantation.
Contraindication ::
Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.
Drug Precautions ::
Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia.
Drug Side Effects ::
Diarrhoea, vomiting, GI haemorrhage and perforation; leucopenia; asthenia, pain, headache, anaemia, thrombocytopenia, renal tubular necrosis, haematuria, BP changes, hyperglycaemia, disturbances of electrolytes and blood lipids, peripheral oedema, dyspnoea, cough, acne, rash, alopecia, dizziness, insomnia, paraesthesia, tremor, hypersensitivity reactions, pancreatitis, hepatitis. Potentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis.
Pregnancy category ::
4
Drug Mode of Action ::
Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes.
Drug Interactions ::
Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.
